ACETAMINOPHEN; BUTALBITAL; CAFFEINE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurolife Pharma Llc	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE	acetaminophen; butalbital; caffeine	CAPSULE;ORAL	204733	ANDA	Aurolife Pharma, LLC	13107-075-01	100 CAPSULE in 1 BOTTLE (13107-075-01)	2017-04-26
Aurolife Pharma Llc	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE	acetaminophen; butalbital; caffeine	CAPSULE;ORAL	204733	ANDA	Aurolife Pharma, LLC	13107-075-05	500 CAPSULE in 1 BOTTLE (13107-075-05)	2017-04-26
Aurolife Pharma Llc	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE	acetaminophen; butalbital; caffeine	CAPSULE;ORAL	204733	ANDA	Aurolife Pharma, LLC	13107-075-30	30 CAPSULE in 1 BOTTLE (13107-075-30)	2017-04-26
Dr Reddys Labs Sa	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE	acetaminophen; butalbital; caffeine	CAPSULE;ORAL	089007	ANDA	Mayne Pharma	51862-179-01	100 CAPSULE in 1 BOTTLE, PLASTIC (51862-179-01)	2012-04-16
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the supply chain for the pharmaceutical drug combining acetaminophen, butalbital, and caffeine. It identifies key suppliers, patent landscapes, and regulatory considerations critical for R&D and investment decisions.

What is the primary therapeutic use of acetaminophen, butalbital, and caffeine combinations?

Acetaminophen, butalbital, and caffeine combinations are primarily used for the relief of tension headaches. Acetaminophen provides analgesic effects, butalbital is a sedative and muscle relaxant, and caffeine is a vasoconstrictor and enhances the analgesic effect of acetaminophen. [1]

Who are the major manufacturers and suppliers of acetaminophen, butalbital, and caffeine API?

The supply chain for this combination drug involves sourcing active pharmaceutical ingredients (APIs) for each component.

Acetaminophen Suppliers

Acetaminophen is a widely produced API with numerous global suppliers. Key players include:

Granules India Ltd.: A significant producer with manufacturing facilities in India. [2]
Mallinckrodt Pharmaceuticals: A diversified global manufacturer with acetaminophen production capabilities.
Anqiu Zhongtai Pharmaceutical Co., Ltd.: A Chinese API manufacturer. [3]
Sami-Recinella: An Italian pharmaceutical company with acetaminophen production.

The market for acetaminophen is highly competitive, with pricing influenced by raw material costs and global production capacity.

Butalbital Suppliers

Butalbital is a barbiturate and its production is more specialized and regulated due to its controlled substance status. Key suppliers include:

Jubilant Life Sciences Ltd.: A global integrated pharmaceutical company with a history of producing various APIs, including controlled substances. [4]
Höfer & Beilschmidt GmbH: A German company specializing in pharmaceutical raw materials and intermediates.
Mylan N.V. (now Viatris): While Mylan has a broad API portfolio, specific butalbital production details are proprietary.

The sourcing of butalbital requires strict adherence to controlled substance regulations, impacting lead times and supplier selection.

Caffeine Suppliers

Caffeine is a commonly available substance with a diverse supplier base, including both pharmaceutical-grade and food-grade manufacturers. Pharmaceutical-grade caffeine suppliers include:

Guanzghou Haoxiang Industrial Co., Ltd.: A Chinese supplier of pharmaceutical raw materials. [5]
Kao Corporation: A Japanese chemical and cosmetics company that also produces pharmaceutical-grade caffeine.
Wuxi AppTec: A contract research, development, and manufacturing organization that can supply various APIs, including caffeine.

While caffeine is readily available, pharmaceutical-grade purity and compliance with pharmacopoeial standards (e.g., USP, EP) are critical.

What is the patent landscape for acetaminophen, butalbital, and caffeine combination products?

The primary patents protecting the original combination formulations have long expired. The patent landscape now focuses on:

New Formulations: Patents for novel delivery systems (e.g., extended-release, orally disintegrating tablets), improved bioavailability, or reduced side effects.
Manufacturing Processes: Patents for more efficient or cost-effective methods of synthesizing the APIs or the final drug product.
Dosage Regimens: Patents for specific dosing schedules or combinations with other therapeutic agents.
Therapeutic Uses: Patents for new indications or patient populations for the existing combination.

Example of a patent strategy: A company might patent an extended-release formulation designed to reduce the frequency of dosing or a method for synthesizing butalbital with higher purity.

Current patent filings often relate to process improvements or specific polymorphs rather than the core molecule itself. A thorough freedom-to-operate analysis is essential before market entry.

What regulatory considerations impact the supply chain?

The combination of acetaminophen, butalbital, and caffeine is subject to stringent regulatory oversight due to the controlled substance status of butalbital.

DEA (Drug Enforcement Administration) Regulations (USA)

Butalbital is classified as a Schedule III controlled substance under the Controlled Substances Act. This imposes:

Registration and Licensing: Manufacturers, distributors, and dispensers must be registered with the DEA.
Quotas: The DEA sets annual production quotas for Schedule III substances to prevent diversion and abuse. Suppliers of butalbital operate under these quotas.
Record Keeping: Strict records of all transactions, inventory, and disposal of butalbital are required.
Security: Facilities handling butalbital must meet specific security requirements to prevent theft and diversion. [6]

FDA (Food and Drug Administration) Regulations (USA)

Good Manufacturing Practices (GMP): All API and drug product manufacturing must comply with FDA's GMP regulations (21 CFR Parts 210 and 211). This ensures product quality, safety, and efficacy.
Drug Master Files (DMFs): API manufacturers typically file DMFs with the FDA, containing detailed information about the manufacturing process, facilities, and controls.
Abbreviated New Drug Applications (ANDAs): Generic manufacturers seeking to market a bioequivalent version of a branded acetaminophen, butalbital, and caffeine product must file an ANDA. This requires demonstrating sameness of API, formulation, and manufacturing process, or proving bioequivalence.

International Regulations

Similar regulatory frameworks exist in other major markets (e.g., EMA in Europe, PMDA in Japan) regarding controlled substances, GMP, and drug approval processes. Companies operating globally must navigate these diverse requirements.

What are the risks and challenges in the supply chain?

Butalbital Supply Volatility: Due to DEA quotas and specialized manufacturing, butalbital supply can be subject to disruptions, impacting overall product availability.
Raw Material Price Fluctuations: The cost of raw materials for acetaminophen and caffeine can vary based on market demand, geopolitical events, and production capacity.
Regulatory Compliance Burden: Maintaining compliance with DEA and FDA regulations, especially for controlled substances, requires significant resources and expertise.
Quality Control and Assurance: Ensuring consistent quality across multiple API suppliers and manufacturing sites is paramount.
Geopolitical Instability: Reliance on international API suppliers can expose the supply chain to risks from trade disputes, natural disasters, or political unrest.

What are the opportunities for market participants?

Generic Market Entry: With patent expiries on originator products, there is a continuous opportunity for generic manufacturers to enter the market by demonstrating bioequivalence.
Specialty Formulations: Development of differentiated products, such as improved delivery systems or fixed-dose combinations with other analgesics, can create new market segments.
Supply Chain Optimization: Companies that can establish robust, reliable, and cost-effective supply chains, particularly for butalbital, can gain a competitive advantage.
Contract Manufacturing: Opportunities exist for contract development and manufacturing organizations (CDMOs) with expertise in handling controlled substances and adhering to stringent GMP standards.

Key Takeaways

The supply chain for acetaminophen, butalbital, and caffeine combination drugs is characterized by a diverse API supplier base for acetaminophen and caffeine, contrasted with a more specialized and regulated market for butalbital. Regulatory compliance, particularly with DEA and FDA mandates concerning controlled substances and GMP, is a critical factor for all participants. The patent landscape primarily involves second-generation patents on formulations and manufacturing processes, offering opportunities for generic manufacturers and innovators developing differentiated products. Supply chain risks are largely concentrated around butalbital availability and general raw material price volatility, while opportunities lie in generic market penetration, specialty formulations, and optimized supply chain management.

FAQs

How do DEA quotas for butalbital affect the availability of this combination drug? DEA quotas limit the total amount of butalbital that can be manufactured or imported into the US annually. If demand for butalbital-containing products exceeds these quotas, it can lead to shortages of the finished drug. Manufacturers must secure sufficient quota allocations for their production needs.
Are there specific FDA requirements for the purity of acetaminophen and caffeine used in this combination? Yes, APIs must meet the standards outlined in the United States Pharmacopeia (USP) or other recognized pharmacopoeias (e.g., European Pharmacopoeia - EP). This ensures identity, strength, quality, and purity, including limits on impurities and contaminants.
Can a company manufacture generic acetaminophen, butalbital, and caffeine without a patent for the original combination? If the original patents for the combination drug's composition of matter have expired, generic manufacturers can seek approval to market their products. They must file an Abbreviated New Drug Application (ANDA) and demonstrate that their product is bioequivalent to the reference listed drug. However, they must also conduct a freedom-to-operate analysis to ensure they are not infringing on any active formulation, process, or method-of-use patents.
What are the typical lead times for sourcing butalbital API compared to acetaminophen or caffeine? Sourcing butalbital API typically involves longer lead times due to its controlled substance status, requiring specialized handling, storage, and rigorous documentation. This contrasts with acetaminophen and pharmaceutical-grade caffeine, which have more established and potentially shorter supply chains.
What is the primary difference between a Schedule III controlled substance like butalbital and a Schedule II substance? Schedule III substances have a lower potential for abuse compared to Schedule II substances. While both have accepted medical uses, Schedule II drugs have a higher risk of abuse, leading to stricter regulations regarding prescriptions, refills, and dispensing. Butalbital's Schedule III classification still mandates significant regulatory oversight but is less restrictive than Schedule II controls.

Citations

[1] National Center for Biotechnology Information. (2023). Acetaminophen; Butalbital; Caffeine. PubChem Compound Summary for CID 77174. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Acetaminophen-butalbital-caffeine

[2] Granules India Ltd. (n.d.). Active Pharmaceutical Ingredients. Retrieved from https://www.granulesindia.com/products/apis

[3] Anqiu Zhongtai Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from https://www.zhongtaipharm.com/ (Specific product listings may vary and require direct inquiry)

[4] Jubilant Life Sciences Ltd. (n.d.). API Products. Retrieved from https://www.jubilantlifesciences.com/pharmaceuticals/api/ (Specific product listings may vary and require direct inquiry)

[5] Guangzhou Haoxiang Industrial Co., Ltd. (n.d.). Product Catalog. Retrieved from https://www.haoxiangchem.com/ (Specific product listings may vary and require direct inquiry)

[6] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from https://www.dea.gov/drug-scheduling

Suppliers and packagers for generic pharmaceutical drug: ACETAMINOPHEN; BUTALBITAL; CAFFEINE